CTLA4 and cancer: Immunoevasion is accomplished by a variety of means, but the strategy of reactivating the immune system as an cancer therapeutic strategy has largely focussed on blocking the checkpoint inhibitor PD-1/PD-L1 and CTLA-4 pathways to enable tumour-reactive T cells to muster effective antitumor responses [45,46,47].